Implanted renal replacement for end-stage renal disease

Panminerva Medica

Volumn 53, Issue 3, 2011, Pages 155-166

  Roy, S ^a   Goldman, K G ^b   Marchant, R E ^c   Zydney, A L ^d   Brown, D L ^e   Fleischman, A J ^f   Conlisk, A T ^g   Desai, T A ^a   Duffy, S ^h   Humes, H D ^e,i   Fissell, W H ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b H Cubed Inc N   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d The Pennsylvania State University   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g The Ohio State University   (United States)

^h Connecticut Reserve Technologies ^*  (United States)

ⁱ Biotherapies Inc   (United States)

Author keywords

Artificial kidney; Dialysis; Renal disease

Indexed keywords

ARTICLE; ARTIFICIAL MEMBRANE; BIOMIMETICS; CHRONIC KIDNEY FAILURE; HUMAN; METHODOLOGY; PROSTHESES AND ORTHOSES; RENAL REPLACEMENT THERAPY;

BIOMIMETICS; HUMANS; KIDNEY FAILURE, CHRONIC; MEMBRANES, ARTIFICIAL; PROSTHESES AND IMPLANTS; RENAL REPLACEMENT THERAPY;

EID: 80054744814     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. US Renal Data System, USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. 2009, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda.
2. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009;302:1782-9.
3. Lumpaopong A, Mathew AV, John E, Jelnin V, Benedetti E, Testa G et al. Early coronary calcification in children and young adults with end-stage renal disease. Transplant Proc 2007;39:37-9. (Pubitemid 46175957)
4. Bonello L, De Labriolle A, Roy P, Steinberg DH, Okabe T, Pinto Slottow TL et al. Impact of optimal medical therapy and revascularization on outcome of patients with chronic kidney disease and on dialysis who presented with acute coronary syndrome. Am J Cardiol 2008;102:535-40.
5. Hreybe H, Ezzeddine R, Bedi M, Barrington W, Bazaz R, Ganz LI et al. Renal insufficiency predicts the time to first appropriate defibrillator shock. Am Heart J 2006;151:852-6.
6. Hreybe H, Razak E, Saba S. Effect of end-stage renal failure and hemodialysis on mortality rates in implantable cardioverter-defibrillator recipients. Pacing Clin Electrophysiol 2007;30:1091-5. (Pubitemid 47300648)
7. Burton JO, Jefferies HJ, Selby NM, Mclntyre CW. Hemodialysisinduced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol 2009;4:914-20.
8. Burton, J.O. et al. Hemodialysis-induced left ventricular dysfunction is associated with an increase in ventricular arrhythmias. Renal Failure, 2008. 30(7): p. 701-9.
9. Burton JO, Jefferies HJ, Selby NM, Mclntyre CW. Hemodialysisinduced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clin J Am Soc Nephrol 2009;4:1925-31.
10. Hothi DK, Rees L, Marek J, Burton J, Mclntyre CW. Pediatrie myocardial stunning underscores the cardiac toxicity of conventional hemodialysis treatments. Clin J Am Soc Nephrol 2009;4:790-7.
11. Ramezani A, Esiamifar A, Banifazl M, Ahmadi F, Maziar S, Razeghi E et al. Efficacy and long-term immunogenicity of hepatitis B vaccine in haemodialysis patients. Int J Clin Pract 2009;63:394-7.
12. Ramezani A, Velayati AA, Eslamifar A, Banifazl M, Ahmadi F, Maziar S et al. Persistence of hepatitis B vaccine immunity in hemodialysis patients. Ther Apher Dial 2008;12:143-6. (Pubitemid 351490248)
13. Tsouchnikas I, Dounousi E, Xanthopoulou K, Papakonstantinou S, Thomoglou V, Tsakiris D. Loss of hepatitis B immunity in hemodialysis patients acquired either naturally or after vaccination. Clin Nephrol 2007;68:228-34. (Pubitemid 47527443)
14. Schulman SL, Deforest A, Kaiser BA, Polinsky MS, Baluarte HJ. Response to measles-mumps-rubella vaccine in children on dialysis. Pediatr Nephrol 1992;6:187-9.
15. Poggio ED, Clemente M, Hricik DE, Heeger PS. Panel of reactive t cells as a measurement of primed cellular alloimmunity in kidney transplant candidates. J Am Soc Nephrol 2006;17:564-72.
16. Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end-stage renal disease. Chest 2001;120:1883-7. (Pubitemid 34053449)
17. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, McAllister CJ, Alcorn H Jr, Kopple JD et al. Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplan 2005;20:1880-8. (Pubitemid 41222603)
18. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:51930.
19. Chan CT, Floras JS, Miller JA, Richardson RM, Pierratos A. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 2002;61:2235-9. (Pubitemid 34539341)
20. Bergman A, Fenton SS, Richardson RM, Chan CT. Reduction in cardiovascular related hospitalization with nocturnal home hemodialysis. Clin Nephrol 2008;69:33-9.
21. WaIi RK, Wang GS, Gottlieb SS, Bellumkonda L, Hansalia R, Ramos E et al. Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol 2005;45:105160.
22. Barua M, Hladunewich M, Keunen J, Pierratos A, McFarlane P, Sood M et al. Successful pregnancies on nocturnal home hemodialysis.[see comment]. Clin J Am Soc Nephrol 2008;3:392-6.
23. Pauly RP, Gill JS, Rose CL, Asad RA, Chery A, Pierratos A et al. Survival among nocturnal home haemodialysis patients compared to kidney transplant recipients. Nephrol Dial Transplant 2009;24:2915-9.
24. Shaldon S. The true history of home haemodialysis. Nephrol Dial Transplant 2005;20:1766.
25. Blagg CR, Blagg CR. The early history of dialysis for chronic renal failure in the United States: a view from Seattle. Am J Kidney Dis 2007;49:482-96.
26. Blagg CR. A brief history of home hemodialysis. Advances in Renal Replacement Therapy 1996;3:99-105.
27. Kjellstrand CM, Blagg CR, Bower J, Twardowski ZJ. The Aksys personal hemodialysis system. Semin Dial 2004;17:151-3. (Pubitemid 38560989)
28. Clark WR, Turk JE Jr. The NxStage System One. Semin Dial 2004;17:167-70. (Pubitemid 38560995)
29. Concepcion DB. Aksys vs. NxStage: a provider's experience. Nephrol News Issues 2006,20:38.
30. Floramo S. Use of the NxStage system one for daily home hemodialysis. Nephrol News Issues 2006;20:48-50.
31. McLaughlin K, Jones H, VanderStraeten C, Mills C, Visser M, Taub K et al. Why patients with ESRD do not select self-care dialysis as a treatment option. Am J Kidney Dis 2003;41:380-5. (Pubitemid 36152457)
32. Cafazzo JA, Leonard K, Easty AC, Rossos PG, Chan CT. Patientperceived barriers to the adoption of nocturnal home hemodialysis. Clin J Am Soc Nephrol 2009;4:784-9.
33. Nissenson AR, Ronco C. Nanotechnology and dialysis. Int J Artificial Organs 2004;27:3-5. (Pubitemid 38268256)
34. Gura V, Davenport A, Beizai M, Ezon C, Ronco C. Beta2-microglobulin and phosphate clearances using a wearable artificial kidney: a pilot study. Am J Kidney Dis 2009;54:104-11.
35. Gura V, Ronco C, Nalesso F, Brendolan A, Beizai M, Ezon C et al. A wearable hemofilter for continuous ambulatory ultrafiltration, [see comment]. Kidney Int 2008;73:497-502. (Pubitemid 351186292)
36. Ronco C, Davenport A, Gura V. A wearable artificial kidney: dream or reality? Nat Clin Pract Nephrol 2008;4:604-5.
37. Kanani DM, Fissell WH, Roy S, Dubnisheva A, Fleischman A, Zydney AL. Permeability-selectivity analysis for ultrafiltration: Effect of pore geometry. J Memb Sei 2010;349:405-10.
38. Fissell WH, Dyke DB, Weitzel WF, Buffington DA, Westover AJ, MacKay SM et al. Bioartificial kidney alters cytokine response and hemodynamics in endotoxin-challenged uremic animals. Blood Purification 2002;20:55-60. (Pubitemid 34102509)
39. Fissell WH, Lou L, Abrishami S, Buffington DA, Humes HD et al. Bioartificial kidney ameliorates gram-negative bacteriainduced septic shock in uremic animals. J Am Soc Nephrol 2003;14:454-61. (Pubitemid 36150870)
40. Humes HD, Buffington DA, Lou L, Abrishami S, Wang M, Xia J et al. Cell therapy with a tissue-engineered kidney reduces the multiple-organ consequences of septic shock. Crit Care Med 2003;31:2421-8. (Pubitemid 37281724)
41. Humes HD, Weitzel WF, Bartlett RH, Swaniker FC, Paganini EP, Luderer JR et al. Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. Kidney Int 2004;66:1578-88. (Pubitemid 39298393)
42. Tumlin J, WaIi R, Williams W, Murray P, Tolwani AJ, Vinnikova AK et al. Efficacy and safety of renal tubule cell therapy for acute renal failure. J Am Soc Nephrol 2008;19:1034-40.
43. Fissell WH, Dubnisheva A, Eldridge AN, Fleischman AJ, Zydney AL, Roy S. High-performance silicon nanopore hemofiltration membranes. J Memb Sei 2009;326:58-63.
44. Fissell WH, Manley S, Dubnisheva A, Glass J, Magistrelli J, Eldridge AN et al. Ficoll is not a rigid sphere. Am J Physiol Renal Physiol 2007;293:FI209-13.
45. Desai TA, Hansford DJ, Ferrari M. Nanopore technology for biomedical applications. Biomed Microdevices 1999;2:11-40. (Pubitemid 129644453)
46. Groszek J, Li L, FerreII N, Smith R, Zorman CA, Hofmann CL et al. Molecular conformation and filtration properties of anionic Ficoll. Am J Physiol Renal Physiol 2010;299:F752-F757.
47. Sharma S, Desai TA. Nanostructured antifouling poly(ethylene glycol) films for silicon-based microsystems. J Nanosci Nanotechnol 2005;5:235-43. (Pubitemid 44502228)
48. Popat KC, Desai TA. Polyethylene glycol) interfaces: an approach for enhanced performance of microfluidic systems. Biosens Bioelectron 2004; 19:1037-44. (Pubitemid 38264488)
49. Muthusubramaniam L, Lowe R, Fissell WH, Li L, Marchant RE, Desai TA et al. Hemocompatibility of silicon-based substrates for biomedical implant applications. Ann Biomed Eng 2011;39:1296305.
50. Sharma S, Johnson RW, Desai TA. Evaluation of the stability of nonfouling ultrathin poly(ethylene glycol) films for silicon-based microdevices. Langmuir 2004;20:348-56.
51. Melvin ME, Fissell WH, Roy S, Brown DL. Silicon Induces Minimal Thromboinflammatory Response During 28-Day Intravascular Implant Testing. ASAIO J 2010;56:344-8.
52. Li L, Marchant RE, Dubnisheva A, Roy S, Fissell WH. Anti-biofouling sulfobetaine polymer thin films on silicon and silicon nanopore membranes. J Biomater Sei Polym Ed 2010 [Epub ahead of print].
53. Holland NB, Qiu Y, Ruegsegger M, Marchant RE. Biomimetic en-gineering of non-adhesive glycocalyx-like surfaces using oligosaccharide surfactant polymers. Nature 1998;392:799-801.
54. Humes HD, Buffington DA, MacKay SM, Funke AJ, Weitzel WF. Replacement of renal function in uremic animals with a tissue-engineered kidney. Nat Biotechnol 1999;17:451-5. (Pubitemid 29217896)
55. Humes HD, Fissell WH, Weitzel WF, Buffington DA, Westover AJ, MacKay SM et al. Metabolic replacement of kidney function in uremic animals with a bioartificial kidney containing human cells. Am J Kid Dis 2002;39:1078-87. (Pubitemid 34454228)
56. Humes HD, Krauss JC, Cieslinski DA, Funke AJ. Tubulogenesis from isolated single cells of adult mammalian kidney: clonal analysis with a recombinant retrovirus. Am J Physiol 1996;271:F42-F49.
57. Humes HD, Fissell WH, Weitzel WF. The bioartificial kidney in the treatment of acute renal failure. Kidney International - Supplement 2002:121-5.
58. Fissell WH, Manley S, Westover A, Humes HD, Fleischman AJ, Roy S. Differentiated growth of human renal tubule cells on thinfilm and nanostructured materials. ASAIO Journal 2006;52:221-7. (Pubitemid 44314869)